Global Atopic Dermatitis (AD) Market: Analysis By Therapy (Biologic, Oral, Topical, Photo), End User, Pipeline, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)
EXECUTIVE SUMMARY
Global Atopic Dermatitis Market was valued at USD 9095.16 Million in the year 2018. Rise in pollution levels, growing urbanization, unhealthy lifestyle, increase in number of allergies backed by hygiene hypothesis are the factors leading to increasing prevalence of atopic dermatitis globally. It is the most common form of eczema, for which no permanent cure is available but novel therapies are being introduced in the market to subdue the itch and discomfort associated with AD.
Topical therapy is the highlight of the AD market, because of easy application on the skin and higher effectiveness. But with the advent of first biologic targeted therapy Dupixent in 2017 (Collaboration between Sanofi and Regeneron) in major regions of the world, AD market has experienced major revenue boost and it is expected to grow exponentially in the forecast period. Moreover Atopic Dermatitis market is also expected to grow because of elaborate pipeline by pharmaceutical companies. Also, by end user hospital may experience maximum growth as number of patient visit for AD, asthma, allergy and hay fever treatment is expected to increase during the forecast period.
Among the regions, Asia Pacific, followed by Americas and Europe will experience the highest growth rate owing to increase in prevalence as well as per capita expenditure on healthcare.
SCOPE OF THE REPORT
Global Atopic Dermatitis Market was valued at USD 9095.16 Million in the year 2018. Rise in pollution levels, growing urbanization, unhealthy lifestyle, increase in number of allergies backed by hygiene hypothesis are the factors leading to increasing prevalence of atopic dermatitis globally. It is the most common form of eczema, for which no permanent cure is available but novel therapies are being introduced in the market to subdue the itch and discomfort associated with AD.
Topical therapy is the highlight of the AD market, because of easy application on the skin and higher effectiveness. But with the advent of first biologic targeted therapy Dupixent in 2017 (Collaboration between Sanofi and Regeneron) in major regions of the world, AD market has experienced major revenue boost and it is expected to grow exponentially in the forecast period. Moreover Atopic Dermatitis market is also expected to grow because of elaborate pipeline by pharmaceutical companies. Also, by end user hospital may experience maximum growth as number of patient visit for AD, asthma, allergy and hay fever treatment is expected to increase during the forecast period.
Among the regions, Asia Pacific, followed by Americas and Europe will experience the highest growth rate owing to increase in prevalence as well as per capita expenditure on healthcare.
SCOPE OF THE REPORT
- The report analyses Atopic Dermatitis Market By Therapy Segment (Biologic Therapy, Topical Therapy, Oral Therapy, Photo Therapy).
- The report assesses the Atopic Dermatitis market By End User (Hospital, Clinics, Research Labs).
- The Global Atopic Dermatitis Market has been analysed By Region (Americas, Europe, Asia Pacific, Rest of the world) and By Country (USA, Canada, Mexico, Brazil, Germany, UK, Japan, China, India, Australia).
- The key insights of the report have been presented through the frameworks of SWOT and Market Attractiveness charts. The attractiveness of the market has been presented by Region, Therapy and by End User. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report provides a detailed pipeline analysis of drugs being developed to cure the problem of atopic dermatitis.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Sanofi, Regeneron, Pfizer, Allergan, Abbvie, Leo Pharma, Lilly, Aclaris, Anaptys Bio, Dermira.
- The report presents the analysis of Atopic Dermatitis market for the historical period of 2014-2018 and the forecast period of 2019-2024.
- Pharmaceutical Companies
- Consulting and Advisory Firms
- Medical Practitioners
- Regulatory Authorities
1. REPORT SCOPE & METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
2.1 Emphasis on Biologic Therapy
2.2 Focus on Developing Economies
3. GLOBAL ATOPIC DERMATITIS MARKET: PRODUCT OUTLOOK
4. GLOBAL ATOPIC DERMATITIS MARKET: AN ANALYSIS
4.1 Market Size, Growth, Forecast (2014-2024)
5. GLOBAL ATOPIC DERMATITIS MARKET SEGMENTATION
5.1 Competitive Scenario of Atopic Dermatitis: By Therapy
5.2 Biologic Therapy – Market Size and Forecast (2019-2024)
5.3 Oral Therapy - Market Size and Forecast (2019-2024)
5.4 Topical Therapy - Market Size and Forecast (2019-2024)
5.5 Phototherapy - Market Size and Forecast (2019-2024)
6. GLOBAL ATOPIC DERMATITIS MARKET SEGMENTATION BY END USER
6.1 Competitive Scenario of Global Atopic Dermatitis: By End User
6.2 Hospitals – Market Size and Forecast (2019-2024)
6.3 Clinics- Market Size and Forecast (2019-2024)
6.4 Research Labs – Market Size and Forecast (2019-2024)
7. GLOBAL ATOPIC DERMATITIS MARKET: REGIONAL ANALYSIS
7.1 Competitive Scenario of Global Atopic Dermatitis: By Region
8.AMERICAS ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
8.1 Americas Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.2 Americas Atopic Dermatitis Market – Prominent Companies
8.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
8.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
8.5 Americas Atopic Dermatitis Market: Country Analysis
8.6 Market Opportunity Chart of Americas Atopic Dermatitis Market- By Country, By Value (Year-2024)
8.7 Competitive Scenario of Americas Atopic Dermatitis : Country Analysis
8.8 United States Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.9 United States Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.10 Canada Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.11 Canada Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.12 Mexico Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.13 Mexico Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.14 Brazil Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.15 Brazil Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.16 Rest of Americas Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.17 Rest of Americas Atopic Dermatitis Market Segmentation By Therapy, End User (2019-2024)
9. EUROPE ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
9.1 Europe Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.2 Europe Atopic Dermatitis Market – Prominent Companies
9.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
9.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
9.5 Europe Atopic Dermatitis Market: Country Analysis
9.6 Market Opportunity Chart of Europe Atopic Dermatitis Market- By Country, By Value (Year-2024)
9.7 Competitive Scenario of Europe Atopic Dermatitis : Country Analysis
9.8 Germany Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.9 Germany Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
9.10 UK Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.11 UK Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
9.12 Rest of Europe Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.13 Rest of Europe Atopic Dermatitis Market Segmentation By Therapy, End User (2019-2024)
10. ASIA PACIFIC ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
10.1 Asia Pacific Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.2 Asia Pacific Atopic Dermatitis Market – Prominent Companies
10.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
10.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
10.5 Asia Pacific Atopic Dermatitis Market: Country Analysis
10.6 Market Opportunity Chart of Asia Pacific Atopic Dermatitis Market- By Country, By Value (Year-2024)
10.7 Competitive Scenario of Asia Pacific Atopic Dermatitis : Country Analysis
10.8 Japan Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.9 Japan Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.10 China Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.11 China Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.12 India Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.13 India Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.14 Australia Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.15 Australia Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.16 Rest of Asia Pacific Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.17 Rest of Asia Pacific Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
11. ROW ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
11.1 ROW Atopic Dermatitis Market: Size and Forecast (2019-2024)
11.2 ROW Atopic Dermatitis Segmentation By Therapy (Biologic, Oral, Topical, photo)
11.3 ROW Atopic Dermatitis Segmentation By End User (Hospitals, Clinics, Research Labs)
12. GLOBAL ATOPIC DERMATITIS MARKET DYNAMICS
12.1 Global Atopic Dermatitis Market Drivers
12.2 Global Atopic Dermatitis Market Restraints
12.3 Global Atopic Dermatitis Market Trends
13. MARKET ATTRACTIVENESS AND KEY DEVELOPMENTS
13.1 Market Attractiveness Chart of Global Atopic Dermatitis Market – By Therapy (Year 2024)
13.2 Market Attractiveness Chart of Global Atopic Dermatitis Market – By End User (Year 2024)
13.3 Market Attractiveness Chart of Global Atopic Dermatitis Market – By Region (Year 2024)
13.4 Key Developments in Atopic Dermatitis Market
14. PIPELINE DRUGS ANALYSIS - ATOPIC DERMATITIS
15. COMPETITIVE LANDSCAPE
15.1 Market Share Analysis
15.2 Competitive Positioning (Leaders, Challengers, Followers, Niche Players)
15.3 SWOT Analysis
15.4 Porter’s Five Force Analysis
16. COMPANY ANALYSIS (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)
16.1 Sanofi
16.2 Regeneron
16.3 Pfizer
16.4 Allergan
16.5 Abbvie
16.6 Leo Pharma
16.7 Lilly
16.8 Aclaris Therapeutics
16.9 Anaptys Bio
16.10 Dermira
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
2.1 Emphasis on Biologic Therapy
2.2 Focus on Developing Economies
3. GLOBAL ATOPIC DERMATITIS MARKET: PRODUCT OUTLOOK
4. GLOBAL ATOPIC DERMATITIS MARKET: AN ANALYSIS
4.1 Market Size, Growth, Forecast (2014-2024)
5. GLOBAL ATOPIC DERMATITIS MARKET SEGMENTATION
5.1 Competitive Scenario of Atopic Dermatitis: By Therapy
5.2 Biologic Therapy – Market Size and Forecast (2019-2024)
5.3 Oral Therapy - Market Size and Forecast (2019-2024)
5.4 Topical Therapy - Market Size and Forecast (2019-2024)
5.5 Phototherapy - Market Size and Forecast (2019-2024)
6. GLOBAL ATOPIC DERMATITIS MARKET SEGMENTATION BY END USER
6.1 Competitive Scenario of Global Atopic Dermatitis: By End User
6.2 Hospitals – Market Size and Forecast (2019-2024)
6.3 Clinics- Market Size and Forecast (2019-2024)
6.4 Research Labs – Market Size and Forecast (2019-2024)
7. GLOBAL ATOPIC DERMATITIS MARKET: REGIONAL ANALYSIS
7.1 Competitive Scenario of Global Atopic Dermatitis: By Region
8.AMERICAS ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
8.1 Americas Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.2 Americas Atopic Dermatitis Market – Prominent Companies
8.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
8.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
8.5 Americas Atopic Dermatitis Market: Country Analysis
8.6 Market Opportunity Chart of Americas Atopic Dermatitis Market- By Country, By Value (Year-2024)
8.7 Competitive Scenario of Americas Atopic Dermatitis : Country Analysis
8.8 United States Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.9 United States Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.10 Canada Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.11 Canada Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.12 Mexico Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.13 Mexico Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.14 Brazil Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.15 Brazil Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
8.16 Rest of Americas Atopic Dermatitis Market: Size and Forecast (2019-2024)
8.17 Rest of Americas Atopic Dermatitis Market Segmentation By Therapy, End User (2019-2024)
9. EUROPE ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
9.1 Europe Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.2 Europe Atopic Dermatitis Market – Prominent Companies
9.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
9.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
9.5 Europe Atopic Dermatitis Market: Country Analysis
9.6 Market Opportunity Chart of Europe Atopic Dermatitis Market- By Country, By Value (Year-2024)
9.7 Competitive Scenario of Europe Atopic Dermatitis : Country Analysis
9.8 Germany Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.9 Germany Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
9.10 UK Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.11 UK Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
9.12 Rest of Europe Atopic Dermatitis Market: Size and Forecast (2019-2024)
9.13 Rest of Europe Atopic Dermatitis Market Segmentation By Therapy, End User (2019-2024)
10. ASIA PACIFIC ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
10.1 Asia Pacific Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.2 Asia Pacific Atopic Dermatitis Market – Prominent Companies
10.3 Market Segmentation By Therapy (Biologic, Oral, Topical, photo)
10.4 Market Segmentation By End User (Hospitals, Clinics, Research Labs)
10.5 Asia Pacific Atopic Dermatitis Market: Country Analysis
10.6 Market Opportunity Chart of Asia Pacific Atopic Dermatitis Market- By Country, By Value (Year-2024)
10.7 Competitive Scenario of Asia Pacific Atopic Dermatitis : Country Analysis
10.8 Japan Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.9 Japan Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.10 China Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.11 China Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.12 India Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.13 India Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.14 Australia Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.15 Australia Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
10.16 Rest of Asia Pacific Atopic Dermatitis Market: Size and Forecast (2019-2024)
10.17 Rest of Asia Pacific Atopic Dermatitis Market Segmentation By Therapy, End User, (2019-2024)
11. ROW ATOPIC DERMATITIS MARKET: SEGMENTATION BY THERAPY, END USER (2019-2024)
11.1 ROW Atopic Dermatitis Market: Size and Forecast (2019-2024)
11.2 ROW Atopic Dermatitis Segmentation By Therapy (Biologic, Oral, Topical, photo)
11.3 ROW Atopic Dermatitis Segmentation By End User (Hospitals, Clinics, Research Labs)
12. GLOBAL ATOPIC DERMATITIS MARKET DYNAMICS
12.1 Global Atopic Dermatitis Market Drivers
12.2 Global Atopic Dermatitis Market Restraints
12.3 Global Atopic Dermatitis Market Trends
13. MARKET ATTRACTIVENESS AND KEY DEVELOPMENTS
13.1 Market Attractiveness Chart of Global Atopic Dermatitis Market – By Therapy (Year 2024)
13.2 Market Attractiveness Chart of Global Atopic Dermatitis Market – By End User (Year 2024)
13.3 Market Attractiveness Chart of Global Atopic Dermatitis Market – By Region (Year 2024)
13.4 Key Developments in Atopic Dermatitis Market
14. PIPELINE DRUGS ANALYSIS - ATOPIC DERMATITIS
15. COMPETITIVE LANDSCAPE
15.1 Market Share Analysis
15.2 Competitive Positioning (Leaders, Challengers, Followers, Niche Players)
15.3 SWOT Analysis
15.4 Porter’s Five Force Analysis
16. COMPANY ANALYSIS (BUSINESS DESCRIPTION, FINANCIAL ANALYSIS, BUSINESS STRATEGY)
16.1 Sanofi
16.2 Regeneron
16.3 Pfizer
16.4 Allergan
16.5 Abbvie
16.6 Leo Pharma
16.7 Lilly
16.8 Aclaris Therapeutics
16.9 Anaptys Bio
16.10 Dermira
LIST OF FIGURES
Figure 1: Global Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 2: Global Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 3: Global Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 4: Global Asthma Prevalence in all age group (2014-2017)(%)
Figure 5: Total Health Spending of G7 countries (2018)(USD/Capita)
Figure 6: Global Market share By therapy 2018 & 2024
Figure 7: Global Atopic Dermatitis Market- By Biologic Therapy, By Value (USD Million), 2014-2024
Figure 8: Global Atopic Dermatitis Market- By Oral Therapy, By Value (USD Million), 2014-2024
Figure 9: Global Atopic Dermatitis Market- By Topical Therapy, By Value (USD Million), 2014-2024
Figure 10: Global Atopic Dermatitis Market- By Phototherapy, By Value (USD Million), 2014-2024
Figure 11: Global Market Share by End User 2018 & 2024
Figure 12: Global Atopic Dermatitis Market- By Hospital, By Value (USD Million), 2014-2024
Figure 13: Global Atopic Dermatitis Market- By Clinics, By Value (USD Million), 2014-2024
Figure 14: Global Atopic Dermatitis Market- By Research Labs, By Value (USD Million), 2014-2024
Figure 15: Global Market Share by Region 2018 & 2024
Figure 16: Americas in Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 17: Americas Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 18: Americas Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 19: Americas Asthma Prevalence in all age group (2014-2017)(%)
Figure 20: Americas Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 21: Americas Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 22: Market Opportunity Chart of Americas Atopic Dermatitis Market - By Country, By Value (Year-2024)
Figure 23: Americas Atopic Dermatitis Market, By Country, Year 2018 & 2024
Figure 24: United States Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 25: US Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 26: US Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 27: US Asthma Prevalence in all age group (2014-2017)(%)
Figure 28: United States GDP per Capita, 2013-2017 (USD) (In Trillion)
Figure 29: United States Healthcare Cost Per Capita, 2013-2017(USD)
Figure 30: United States Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 31: United States Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 32: Canada Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million
Figure 33: Canada Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 34: Canada Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 35: Canada Asthma Prevalence in all age group (2014-2017)(%)
Figure 36: Canada GDP, 2013-2017 (USD) (In Trillion)
Figure 37: Canada Healthcare Cost Per Capita, 2013-2017 (%)
Figure 38: Canada Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 39: Canada Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 40: Mexico Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 41: Mexico Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 42: Mexico Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 43: Mexico Asthma Prevalence in all age group (2014-2017)(%)
Figure 44: Mexico GDP, 2013-2017 (USD) (In Trillion)
Figure 45: Mexico Healthcare Cost Per Capita, 2013-2017 (%)
Figure 46: Mexico Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 47: Mexico Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 48: Brazil Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 49: Brazil Atopic Dermatitis Prevalence in age group under 5 years. (2014-2017)(%)
Figure 50: Brazil Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 51: Brazil Asthma Prevalence in all age group (2014-2017)(%)
Figure 52: Brazil Health Spending as percent of GDP, 2013-2016 (%)
Figure 53: Brazil GDP , 2013-2017 (USD) (In Trillion)
Figure 54: Brazil Healthcare Cost Per Capita, 2013-2016(%)(Expected)
Figure 55: Brazil Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 56: Brazil Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 57: Rest of Americas Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 58: Rest of Americas Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 59: Rest of Americas Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 60: Europe Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 61: Europe Atopic Dermatitis Prevalence in age group under 5 years. (2014-2017)(%)
Figure 62: Europe Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 63: Europe Asthma Prevalence in all age group (2014-2017)(%)
Figure 64: European Union current Health Expenditure (2012-2016)(% of GDP)
Figure 65: Europe Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 66: Europe Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 67: Market Opportunity Chart of Europe Atopic Dermatitis Market - By Country, By Value (Year-2024)
Figure 68: Europe Atopic Dermatitis Market, By Country, Year 2018 & 2024
Figure 69: Germany Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 70: Germany Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 71: Germany Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 72: Germany Asthma Prevalence in all age group (2014-2017)(%)
Figure 73: Germany GDP, 2013-2017 (USD) (In Trillion)
Figure 74: Germany Healthcare Cost Per Capita, 2014-2018 (%)
Figure 75: Germany Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 76: Germany Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 77: UK Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 78: UK Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 79: UK Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 80: UK Asthma Prevalence in all age group (2014-2017)(%)
Figure 81: UK GDP, 2013-2017 (USD) (In Trillion)
Figure 82: UK Healthcare Cost Per Capita, 2014-2018 (%)
Figure 83: United Kingdom Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 84: United Kingdom Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 85: Rest of Europe Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 86: Rest of Europe Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 87: Rest of Europe Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 88: Asia Pacific Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 89: Asia Atopic Dermatitis Prevalence in all age. (2014-2017)(In Million)
Figure 90: Asia Atopic Dermatitis Prevalence in age group 5-14 years.(2014-2017)(In Million)
Figure 91: Asia Asthma Prevalence in all age group (2014-2017)(%)
Figure 92: East Asia and Pacific current Health Expenditure (2013-2016)(% of GDP)
Figure 93: Asia Pacific Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 94: Asia Pacific Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 95: Market Opportunity Chart of Asia Pacific Atopic Dermatitis Market - By Country, By Value (Year-2024)
Figure 96: Asia Pacific Atopic Dermatitis Market, By Country, Year 2018 & 2024
Figure 97: Japan Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 98: Japan Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 99: Japan Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 100: Japan Asthma Prevalence in all age group (2014-2017)(%)
Figure 101: Japan GDP , 2013-2017 (USD) (In Trillion)
Figure 102: Japan Healthcare Cost Per Capita, 2013-2017 (%)
Figure 103: Japan Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 104: Japan Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 105: China Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 106: China Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(In Millions)
Figure 107: China Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 108: China Asthma Prevalence in all age group (2014-2017)(%)
Figure 109: China GDP, 2013-2017 (USD) (In Trillion)
Figure 110: China Healthcare Cost Per Capita, 2013-2016 (%)
Figure 111: China Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 112: China Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 113: India Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 114: India Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 115: India Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 116: India Asthma Prevalence in all age group (2014-2017)(%)
Figure 117: India GDP, 2013-2017 (USD) (In Trillion)
Figure 118: India Healthcare Cost Per Capita, 2013-2016 (%)
Figure 119: India Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 120: India Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 121: Australia Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 122: Australia Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(In Thousands)
Figure 123: Australia Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(In Thousands)
Figure 124: Australia Asthma Prevalence in all age group (2014-2017)(%)
Figure 125: Australia Current Health Expenditure per capita (2013-2016)(current USD)
Figure 126: Australia Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 127: Australia Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 128: Rest of Asia Pacific Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 129: Rest of Asia Pacific Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 130: Rest of Asia Pacific Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 131: Rest of World Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 132: North Africa & Middle East AD Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 133: North Africa & Middle East AD Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 134: North Africa & Middle East Asthma Prevalence in all age group (2014-2017)(%)
Figure 135: North Africa & Middle East Current Health Expenditure per capita (2013-2016)(current USD)
Figure 136: Rest of World Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 137: Rest of World Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 138: Market Attractiveness Chart of Global Atopic Dermatitis Market - By Therapy (Year-2024)
Figure 139: Market Attractiveness Chart of Global Atopic Dermatitis Market - By End User(Year-2024)
Figure 140: Market Attractiveness Chart of Global Atopic Dermatitis Market - By Region (Year-2024)
Figure 141: Competitive Positions of companies dealing in Atopic Dermatitis (2018)
Figure 142: Sanofi, Net Sales Revenue, 2014-2018 (USD Million)
Figure 143: Sanofi, Net Sales by Operating Segment, 2018 (USD Million)
Figure 144: Sanofi, Net Sales, By Region, In 2018 (%)
Figure 145: Sanofi Net Income, Year 2014-2018(USD MILLION)
Figure 146: Regeneron, Total Revenue, 2014-2018 (USD Million)
Figure 147: Regeneron Net Income, Year 2014-2018 (USD MILLION)
Figure 148: Regeneron, Revenue Segmentation,2014-2018 (USD Million)
Figure 149: Pfizer, Revenue, 2014-2018 (USD Million)
Figure 150: Pfizer, Net Income, 2014-2018 (USD Million)
Figure 151: Pfizer, Revenue, By National Market, 2014-2018 (%)
Figure 152: Pfizer, Revenue by Segment and Geography2018 (USD Million)
Figure 153: Pfizer, Revenue from Eucrisa(Atopic Dermatitis) (Innovative Health), 2018 (USD Million)
Figure 154: Allergan, Net Revenue, 2014-2018(USD Million)
Figure 155: Allergan, Business Segment Revenue, 2018 (% of Total Net Revenue)
Figure 156: Allergan, Business Segment Revenue, 2017 (% of Total Net Revenue)
Figure 157: Allergan, revenue disaggregated by geography for International Segment 2018 (USD Million)
Figure 158: Abbvie, Net Revenue, 2014-2018 (USD Million)
Figure 159: Abbvie, Net Earnings, 2014-2018 (USD Million)
Figure 160: Abbvie, Sales by Region, 2018 (% of Total Net Revenue)
Figure 161: Abbvie, Sales by Region, 2017(% of Total Net Revenue)
Figure 162: Lilly, Revenue, 2014-2018 (USD Million)
Figure 163: Lilly, Net Income,(loss) 2014-2018 (USD Million)
Figure 164: Lilly Revenue, By Region, In 2018 (%)
Figure 165: Lilly Segment Revenue, 2018 (USD Million)
Figure 166: Aclaris Therapeutics Revenue, 2017-2018 (USD Thousands)
Figure 167: Aclaris Therapeutics, Gross Profit 2017-2018 (USD Thousands)
Figure 168: Aclaris Therapeutics Revenue by Operational segments, 2018 (USD Thousands)
Figure 169: Aclaris Therapeutics Revenue,(Net Loss), 2014-2018 (USD Thousands)
Figure 170: Anaptys Bio Revenue (Loss), 2014-2018 (USD Thousands)
Figure 171: Anaptys Bio, Net Income(Loss) 2014-2018 ,(USD Thousands)
Figure 172: Dermira Collaboration and license Revenue, 2014-2018 (USD Thousands)
Figure 173: Dermira, Net Income(Loss)2014-2018 ,(USD Thousands)
Figure 1: Global Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 2: Global Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 3: Global Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 4: Global Asthma Prevalence in all age group (2014-2017)(%)
Figure 5: Total Health Spending of G7 countries (2018)(USD/Capita)
Figure 6: Global Market share By therapy 2018 & 2024
Figure 7: Global Atopic Dermatitis Market- By Biologic Therapy, By Value (USD Million), 2014-2024
Figure 8: Global Atopic Dermatitis Market- By Oral Therapy, By Value (USD Million), 2014-2024
Figure 9: Global Atopic Dermatitis Market- By Topical Therapy, By Value (USD Million), 2014-2024
Figure 10: Global Atopic Dermatitis Market- By Phototherapy, By Value (USD Million), 2014-2024
Figure 11: Global Market Share by End User 2018 & 2024
Figure 12: Global Atopic Dermatitis Market- By Hospital, By Value (USD Million), 2014-2024
Figure 13: Global Atopic Dermatitis Market- By Clinics, By Value (USD Million), 2014-2024
Figure 14: Global Atopic Dermatitis Market- By Research Labs, By Value (USD Million), 2014-2024
Figure 15: Global Market Share by Region 2018 & 2024
Figure 16: Americas in Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 17: Americas Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 18: Americas Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 19: Americas Asthma Prevalence in all age group (2014-2017)(%)
Figure 20: Americas Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 21: Americas Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 22: Market Opportunity Chart of Americas Atopic Dermatitis Market - By Country, By Value (Year-2024)
Figure 23: Americas Atopic Dermatitis Market, By Country, Year 2018 & 2024
Figure 24: United States Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 25: US Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 26: US Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 27: US Asthma Prevalence in all age group (2014-2017)(%)
Figure 28: United States GDP per Capita, 2013-2017 (USD) (In Trillion)
Figure 29: United States Healthcare Cost Per Capita, 2013-2017(USD)
Figure 30: United States Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 31: United States Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 32: Canada Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million
Figure 33: Canada Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 34: Canada Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 35: Canada Asthma Prevalence in all age group (2014-2017)(%)
Figure 36: Canada GDP, 2013-2017 (USD) (In Trillion)
Figure 37: Canada Healthcare Cost Per Capita, 2013-2017 (%)
Figure 38: Canada Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 39: Canada Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 40: Mexico Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 41: Mexico Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 42: Mexico Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 43: Mexico Asthma Prevalence in all age group (2014-2017)(%)
Figure 44: Mexico GDP, 2013-2017 (USD) (In Trillion)
Figure 45: Mexico Healthcare Cost Per Capita, 2013-2017 (%)
Figure 46: Mexico Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 47: Mexico Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 48: Brazil Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 49: Brazil Atopic Dermatitis Prevalence in age group under 5 years. (2014-2017)(%)
Figure 50: Brazil Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 51: Brazil Asthma Prevalence in all age group (2014-2017)(%)
Figure 52: Brazil Health Spending as percent of GDP, 2013-2016 (%)
Figure 53: Brazil GDP , 2013-2017 (USD) (In Trillion)
Figure 54: Brazil Healthcare Cost Per Capita, 2013-2016(%)(Expected)
Figure 55: Brazil Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 56: Brazil Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 57: Rest of Americas Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 58: Rest of Americas Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 59: Rest of Americas Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 60: Europe Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 61: Europe Atopic Dermatitis Prevalence in age group under 5 years. (2014-2017)(%)
Figure 62: Europe Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 63: Europe Asthma Prevalence in all age group (2014-2017)(%)
Figure 64: European Union current Health Expenditure (2012-2016)(% of GDP)
Figure 65: Europe Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 66: Europe Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 67: Market Opportunity Chart of Europe Atopic Dermatitis Market - By Country, By Value (Year-2024)
Figure 68: Europe Atopic Dermatitis Market, By Country, Year 2018 & 2024
Figure 69: Germany Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 70: Germany Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 71: Germany Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 72: Germany Asthma Prevalence in all age group (2014-2017)(%)
Figure 73: Germany GDP, 2013-2017 (USD) (In Trillion)
Figure 74: Germany Healthcare Cost Per Capita, 2014-2018 (%)
Figure 75: Germany Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 76: Germany Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 77: UK Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 78: UK Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 79: UK Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 80: UK Asthma Prevalence in all age group (2014-2017)(%)
Figure 81: UK GDP, 2013-2017 (USD) (In Trillion)
Figure 82: UK Healthcare Cost Per Capita, 2014-2018 (%)
Figure 83: United Kingdom Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 84: United Kingdom Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 85: Rest of Europe Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 86: Rest of Europe Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 87: Rest of Europe Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 88: Asia Pacific Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 89: Asia Atopic Dermatitis Prevalence in all age. (2014-2017)(In Million)
Figure 90: Asia Atopic Dermatitis Prevalence in age group 5-14 years.(2014-2017)(In Million)
Figure 91: Asia Asthma Prevalence in all age group (2014-2017)(%)
Figure 92: East Asia and Pacific current Health Expenditure (2013-2016)(% of GDP)
Figure 93: Asia Pacific Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 94: Asia Pacific Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 95: Market Opportunity Chart of Asia Pacific Atopic Dermatitis Market - By Country, By Value (Year-2024)
Figure 96: Asia Pacific Atopic Dermatitis Market, By Country, Year 2018 & 2024
Figure 97: Japan Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 98: Japan Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 99: Japan Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 100: Japan Asthma Prevalence in all age group (2014-2017)(%)
Figure 101: Japan GDP , 2013-2017 (USD) (In Trillion)
Figure 102: Japan Healthcare Cost Per Capita, 2013-2017 (%)
Figure 103: Japan Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 104: Japan Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 105: China Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 106: China Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(In Millions)
Figure 107: China Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 108: China Asthma Prevalence in all age group (2014-2017)(%)
Figure 109: China GDP, 2013-2017 (USD) (In Trillion)
Figure 110: China Healthcare Cost Per Capita, 2013-2016 (%)
Figure 111: China Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 112: China Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 113: India Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 114: India Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 115: India Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 116: India Asthma Prevalence in all age group (2014-2017)(%)
Figure 117: India GDP, 2013-2017 (USD) (In Trillion)
Figure 118: India Healthcare Cost Per Capita, 2013-2016 (%)
Figure 119: India Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 120: India Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 121: Australia Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 122: Australia Atopic Dermatitis Prevalence in age group 5-14 years. (2014-2017)(In Thousands)
Figure 123: Australia Atopic Dermatitis Prevalence in age group Under 5 years. (2014-2017)(In Thousands)
Figure 124: Australia Asthma Prevalence in all age group (2014-2017)(%)
Figure 125: Australia Current Health Expenditure per capita (2013-2016)(current USD)
Figure 126: Australia Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 127: Australia Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 128: Rest of Asia Pacific Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 129: Rest of Asia Pacific Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 130: Rest of Asia Pacific Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 131: Rest of World Atopic Dermatitis Market Size, By Value, 2014-2024 (USD Million)
Figure 132: North Africa & Middle East AD Prevalence in age group 5-14 years. (2014-2017)(%)
Figure 133: North Africa & Middle East AD Prevalence in age group Under 5 years. (2014-2017)(%)
Figure 134: North Africa & Middle East Asthma Prevalence in all age group (2014-2017)(%)
Figure 135: North Africa & Middle East Current Health Expenditure per capita (2013-2016)(current USD)
Figure 136: Rest of World Atopic Dermatitis Market- By Therapy, By Value (USD Million), 2014-2024
Figure 137: Rest of World Atopic Dermatitis Market- By End User, By Value (USD Million), 2014-2024
Figure 138: Market Attractiveness Chart of Global Atopic Dermatitis Market - By Therapy (Year-2024)
Figure 139: Market Attractiveness Chart of Global Atopic Dermatitis Market - By End User(Year-2024)
Figure 140: Market Attractiveness Chart of Global Atopic Dermatitis Market - By Region (Year-2024)
Figure 141: Competitive Positions of companies dealing in Atopic Dermatitis (2018)
Figure 142: Sanofi, Net Sales Revenue, 2014-2018 (USD Million)
Figure 143: Sanofi, Net Sales by Operating Segment, 2018 (USD Million)
Figure 144: Sanofi, Net Sales, By Region, In 2018 (%)
Figure 145: Sanofi Net Income, Year 2014-2018(USD MILLION)
Figure 146: Regeneron, Total Revenue, 2014-2018 (USD Million)
Figure 147: Regeneron Net Income, Year 2014-2018 (USD MILLION)
Figure 148: Regeneron, Revenue Segmentation,2014-2018 (USD Million)
Figure 149: Pfizer, Revenue, 2014-2018 (USD Million)
Figure 150: Pfizer, Net Income, 2014-2018 (USD Million)
Figure 151: Pfizer, Revenue, By National Market, 2014-2018 (%)
Figure 152: Pfizer, Revenue by Segment and Geography2018 (USD Million)
Figure 153: Pfizer, Revenue from Eucrisa(Atopic Dermatitis) (Innovative Health), 2018 (USD Million)
Figure 154: Allergan, Net Revenue, 2014-2018(USD Million)
Figure 155: Allergan, Business Segment Revenue, 2018 (% of Total Net Revenue)
Figure 156: Allergan, Business Segment Revenue, 2017 (% of Total Net Revenue)
Figure 157: Allergan, revenue disaggregated by geography for International Segment 2018 (USD Million)
Figure 158: Abbvie, Net Revenue, 2014-2018 (USD Million)
Figure 159: Abbvie, Net Earnings, 2014-2018 (USD Million)
Figure 160: Abbvie, Sales by Region, 2018 (% of Total Net Revenue)
Figure 161: Abbvie, Sales by Region, 2017(% of Total Net Revenue)
Figure 162: Lilly, Revenue, 2014-2018 (USD Million)
Figure 163: Lilly, Net Income,(loss) 2014-2018 (USD Million)
Figure 164: Lilly Revenue, By Region, In 2018 (%)
Figure 165: Lilly Segment Revenue, 2018 (USD Million)
Figure 166: Aclaris Therapeutics Revenue, 2017-2018 (USD Thousands)
Figure 167: Aclaris Therapeutics, Gross Profit 2017-2018 (USD Thousands)
Figure 168: Aclaris Therapeutics Revenue by Operational segments, 2018 (USD Thousands)
Figure 169: Aclaris Therapeutics Revenue,(Net Loss), 2014-2018 (USD Thousands)
Figure 170: Anaptys Bio Revenue (Loss), 2014-2018 (USD Thousands)
Figure 171: Anaptys Bio, Net Income(Loss) 2014-2018 ,(USD Thousands)
Figure 172: Dermira Collaboration and license Revenue, 2014-2018 (USD Thousands)
Figure 173: Dermira, Net Income(Loss)2014-2018 ,(USD Thousands)
LIST OF TABLES
Table A: List Of Some FDA Approved Atopic Dermatitis Drugs
Table B: Topical Steroids according to potency for Atopic Dermatitis Treatment
Table C: Prominent Atopic Dermatitis companies operating in Americas Market
Table D: Prominent Atopic Dermatitis companies operating in Europe Market
Table E: Prominent Atopic Dermatitis companies operating in Asia Pacific Market
Table F: 12. List of Injectables
Table G: List oF Orals
Table H: 12. List of Topicals
Table I: Global Market Share Analysis Of Companies
Table A: List Of Some FDA Approved Atopic Dermatitis Drugs
Table B: Topical Steroids according to potency for Atopic Dermatitis Treatment
Table C: Prominent Atopic Dermatitis companies operating in Americas Market
Table D: Prominent Atopic Dermatitis companies operating in Europe Market
Table E: Prominent Atopic Dermatitis companies operating in Asia Pacific Market
Table F: 12. List of Injectables
Table G: List oF Orals
Table H: 12. List of Topicals
Table I: Global Market Share Analysis Of Companies
